Posts by Peter W. PENG

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.

At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP regimen) as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Results showed a median PFS of 11.8 months and median OS of 27.1 months, with manageable toxicity. The second study, an ongoing trial (Abstract #TPS1122), aims to predict treatment response to T-DXd in HER2-positive breast cancer brain metastases using68Ga-FAPI PET-CT to assess tumor metabolic heterogeneity. The trial is actively recruiting patients.This article specifically introduces two studies.